precision
biosciences
servier
expand
car
oncology
development
collaboration
four
new
programs
targeting
hematological
solid
tumors
durham
paris
globe
newswire
precision
biosciences
nasdaq
dtil
clinical
stage
biotechnology
developing
allogeneic
car
vivo
gene
correction
therapies
genome
editing
platform
collaboration
servier
independent
global
pharmaceutical
company
today
announced
companies
added
two
additional
hematological
cancer
targets
beyond
two
solid
tumor
targets
car
development
commercial
license
agreement
addition
new
targets
build
productive
collaboration
precision
servier
driving
development
lead
allogeneic
car
candidate
targeting
said
matt
kane
ceo
precision
biosciences
pleased
expand
collaboration
servier
apply
proprietary
cell
engineering
unique
allogeneic
car
manufacturing
development
strategies
potentially
extend
reach
car
therapies
beyond
hematological
cancers
solid
terms
existing
development
commercial
license
agreement
servier
precision
servier
selected
two
hematological
two
solid
tumor
targets
beyond
already
precision
allogeneic
car
pipeline
precision
intends
leverage
proprietary
arcus
genome
editing
platform
car
development
manufacturing
expertise
research
development
activities
including
investigational
new
drug
ind
filing
manufacturing
initial
clinical
trial
material
phase
study
servier
right
opt
development
commercialization
precision
right
participate
development
commercialization
licensed
products
resulting
collaboration
option
united
states
addition
new
targets
precision
expects
receive
milestone
payments
precision
also
eligible
option
fees
clinical
regulatory
sales
milestones
addition
royalties
product
sales
servier
partner
purpose
patients
pleased
add
four
additional
targets
beyond
collaboration
precision
biosciences
part
commitment
oncology
said
patrick
therasse
deputy
head
global
rd
oncology
servier
look
forward
utilizing
arcus
genome
editing
platform
new
targets
potentially
develop
several
innovative
allogeneic
car
therapies
patients
range
solid
hematological
investigational
allogeneic
chimeric
antigen
receptor
car
candidate
targeting
phase
multicenter
nonrandomized
parallel
assignment
study
treatment
patients
relapsed
refractory
r
r
lymphoma
nhl
r
r
precursor
acute
lymphoblastic
leukemia
nhl
cohort
includes
patients
mantle
cell
lymphoma
mcl
aggressive
subtype
nhl
precision
received
orphan
drug
fast
track
designations
food
drug
administration
fda
information
study
available
study
identifier
number
precision
allogeneic
car
platform
precision
advancing
pipeline
optimized
allogeneic
car
therapies
leveraging
fully
scaled
proprietary
manufacturing
processes
platform
designed
maximize
number
patients
potentially
benefit
car
therapy
precision
carefully
selects
cells
derived
healthy
donors
starting
material
utilizes
unique
arcus
genome
editing
technology
modify
cells
via
engineering
process
inserting
car
gene
cell
receptor
tcr
locus
process
knocks
car
knocking
tcr
creating
consistent
product
reliably
rapidly
manufactured
designed
prevent
disease
precision
optimizes
car
therapy
candidates
immune
cell
expansion
body
maintaining
high
proportion
na√Øve
central
memory
car
cells
throughout
manufacturing
process
final
product
precision
biosciences
inc
precision
biosciences
clinical
stage
biotechnology
company
dedicated
improving
life
dtil
novel
proprietary
genome
editing
platform
arcus
highly
specific
versatile
genome
editing
platform
designed
therapeutic
safety
delivery
control
mind
using
arcus
company
pipeline
consists
multiple
car
immunotherapy
clinical
candidates
several
vivo
gene
correction
therapy
candidates
potentially
cure
genetic
infectious
diseases
known
adequate
treatments
exist
information
precision
biosciences
available
servier
servier
global
pharmaceutical
company
governed
foundation
headquarters
france
suresnes
strong
international
presence
countries
total
revenue
billion
euros
servier
employs
people
worldwide
entirely
independent
group
invests
average
total
revenue
excluding
generics
every
year
research
development
uses
profits
development
corporate
growth
driven
servier
constant
search
innovation
five
areas
excellence
cardiovascular
neurodegenerative
diseases
cancer
diabetes
well
activities
generic
drugs
servier
also
offers
ehealth
solutions
beyond
drug
development
information
available
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
statements
contained
press
release
relate
matters
historical
fact
considered
statements
including
without
limitation
statements
regarding
company
expectations
milestone
payments
involving
additional
targets
identified
agreement
servier
targets
company
clinical
trial
involving
results
company
car
therapies
including
without
limitation
potential
treatment
hematological
cancers
solid
tumors
cases
identify
statements
terms
aim
anticipate
believe
could
expect
plan
intend
estimate
target
mission
goal
may
would
could
target
potential
project
predict
contemplate
potential
negative
thereof
similar
words
expressions
statements
based
management
current
expectations
beliefs
assumptions
information
currently
available
us
statements
subject
number
known
unknown
risks
uncertainties
assumptions
actual
results
may
differ
materially
expressed
implied
statements
due
various
important
factors
including
limited
ability
become
profitable
ability
procure
sufficient
funding
requirements
current
debt
instruments
effects
restrictions
thereunder
risks
associated
raising
additional
capital
operating
expenses
ability
predict
expenses
limited
operating
history
success
programs
product
candidates
expend
resources
limited
ability
inability
assess
safety
efficacy
product
candidates
dependence
arcus
technology
initiation
cost
timing
progress
achievement
milestones
results
research
development
activities
preclinical
greenhouse
studies
clinical
field
trials
public
perception
genome
editing
technology
applications
competition
genome
editing
biopharmaceutical
biotechnology
agricultural
biotechnology
fields
collaborators
ability
identify
develop
commercialize
product
candidates
pending
potential
liability
lawsuits
penalties
us
collaborators
related
technology
product
candidates
foreign
regulatory
landscape
applicable
collaborators
development
product
candidates
collaborators
ability
obtain
maintain
regulatory
approval
product
candidates
related
restrictions
limitations
warnings
label
approved
product
candidate
collaborators
ability
advance
product
candidates
successfully
design
implement
complete
clinical
field
trials
potential
manufacturing
problems
associated
development
commercialization
product
candidates
ability
obtain
adequate
supply
cells
qualified
donors
ability
achieve
anticipated
operating
efficiencies
manufacturing
facility
delays
difficulties
collaborators
ability
enroll
patients
changes
interim
initial
data
announce
publish
product
candidates
work
intended
cause
undesirable
side
effects
risks
associated
applicable
healthcare
data
protection
privacy
security
regulations
compliance
therewith
rate
degree
market
acceptance
product
candidates
success
existing
collaboration
agreements
ability
enter
new
collaboration
arrangements
current
future
relationships
reliance
third
parties
including
suppliers
manufacturers
ability
obtain
maintain
intellectual
property
protection
technology
product
candidates
potential
litigation
relating
infringement
misappropriation
intellectual
property
rights
ability
effectively
manage
growth
operations
ability
attract
retain
motivate
key
executives
personnel
market
economic
conditions
effects
system
failures
security
breaches
effects
natural
manmade
disasters
public
health
emergencies
natural
catastrophic
events
effects
outbreak
pandemic
epidemic
outbreak
infectious
disease
insurance
expenses
exposure
uninsured
liabilities
effects
tax
rules
risks
related
ownership
common
stock
important
factors
discussed
caption
risk
factors
quarterly
report
form
quarterly
period
ended
june
factors
may
updated
time
time
filings
sec
accessible
sec
website
investors
media
page
website
statements
speak
date
press
release
except
required
applicable
law
plan
publicly
update
revise
statements
contained
herein
whether
result
new
information
future
events
changed
circumstances
otherwise
precision
biosciences
investor
media
contact
maurissa
messier
senior
director
corporate
communications
servier
group
press
contacts
sonia
marques
presse
